Epirubicin plus cyclophosphamide followed by docetaxel plus trastuzumab and bevacizumab as neoadjuvant therapy for HER2-positive locally advanced breast cancer (LABC) or as adjuvant therapy for HER2-positive pathologic stage III breast cancer (PS3BC): A phase II trial of the NSABP Foundation Research Group

被引：0
|
作者：
Smith, J. W. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Buyse, M. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Rastogi, P. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Geyer, C., Jr. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Jacobs, S. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Patocskai, E. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Wolmark, N. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
机构：
[1] Columbia River Oncol Program, Portland, OR USA
[2] IDDI, Louvain, Belgium
[3] NSABP, Pittsburgh, PA USA
[4] UPCI, Magee Womens Hosp, Womens Canc Clin, Pittsburgh, PA USA
[5] Allegheny Gen Hosp, Pittsburgh, PA 15212 USA
[6] Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA
[7] Univ Montreal, Ctr Hosp, Montreal, PQ, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
580
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Efficacy and safety of neoadjuvant pyrotinib plus docetaxel/liposomal doxorubicin/cyclophosphamide for HER2-positive breast cancer
    Chunyu Tian
    Minghui Wang
    Hancheng Liu
    Jianping Liu
    Mengze Xu
    Lihui Ma
    Irish Journal of Medical Science (1971 -), 2023, 192 (3): : 1041 - 1049
  • [32] Efficacy and safety of neoadjuvant pyrotinib plus docetaxel/liposomal doxorubicin/cyclophosphamide for HER2-positive breast cancer
    Tian, Chunyu
    Wang, Minghui
    Liu, Hancheng
    Liu, Jianping
    Xu, Mengze
    Ma, Lihui
    IRISH JOURNAL OF MEDICAL SCIENCE, 2023, 192 (03) : 1041 - 1049
  • [33] Randomized Phase II Trial of First-Line Trastuzumab Plus Docetaxel and Capecitabine Compared With Trastuzumab Plus Docetaxel in HER2-Positive Metastatic Breast Cancer
    Wardley, Andrew M.
    Pivot, Xavier
    Morales-Vasquez, Flavia
    Zetina, Luis M.
    Dias Gaui, Maria de Fatima
    Reyes, Douglas Otero
    Jassem, Jacek
    Barton, Claire
    Button, Peter
    Hersberger, Veronica
    Torres, Antonio Anton
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (06) : 976 - 983
  • [34] Bevacizumab beginning concurrently with a sequential regimen of doxorubicin and cyclophosphamide followed by docetaxel and capecitabine as neoadjuvant therapy followed by postoperative bevacizumab alone for women with HER2-negative locally advanced breast cancer (LABC): A phase II trial of the NSABP Foundation Research Group
    Rastogi, P.
    Buyse, M.
    Swain, S.
    Jacobs, S.
    Robidoux, A.
    Liepman, M.
    Dy, P.
    Geyer, C., Jr.
    Wolmark, N.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [35] Mode of action of pertuzumab in combination with trastuzumab plus docetaxel therapy in a HER2-positive breast cancer xenograft model
    Yamashita-Kashima, Yoriko
    Shu, Sei
    Yorozu, Keigo
    Moriya, Yoichiro
    Harada, Naoki
    ONCOLOGY LETTERS, 2017, 14 (04) : 4197 - 4205
  • [36] Trastuzumab-Based Neoadjuvant Therapy in Patients With HER2-Positive Breast Cancer
    Chang, Helena R.
    CANCER, 2010, 116 (12) : 2856 - 2867
  • [37] Correlation of HER2 codon 655 polymorphism with cardiotoxicity risk in Chinese HER2-positive breast cancer patients undergoing epirubicin/cyclophosphamide followed by docetaxel plus trastuzumab adjuvant chemotherapy
    Tan, Lun
    Su, Xinyu
    Li, Xun
    Li, Hai
    Hu, Bo
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2020, 13 (02): : 286 - 294
  • [38] EVALUATION OF TRASTUZUMAB FOR ADJUVANT THERAPY OF HER2-POSITIVE BREAST CANCER EGYPTIAN FEMALES
    Abbas, N. A. R.
    ANNALS OF ONCOLOGY, 2010, 21 : 44 - 44
  • [39] An Economic Evaluation of Adjuvant Trastuzumab Therapy in HER2-Positive Early Breast Cancer
    Chen, Wen
    Jiang, Zefei
    Shao, Zhimin
    Sun, Qiang
    Shen, Kunwei
    VALUE IN HEALTH, 2009, 12 : S82 - S84
  • [40] Neoadjuvant ixabepilone/carboplatin/trastuzumab in HER2-positive locally advanced breast cancer: A Sarah Cannon Research Institute phase II trial
    Zubkus, J. D.
    Daniel, D. B.
    Eakle, J. F.
    Bechhold, R. G.
    Shastry, M.
    Tucker, P. S.
    Burris, H. A.
    Hainsworth, J. D.
    Yardley, D. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345